ALK and non-small cell lung carcinoma: Twenty-six advanced NSCLC patients who are EGFR and ALK wide type and failed ≤ 4 lines of systemic therapies including platinum-based chemotherapy and PD-1/PD-L1 inhibitor were enrolled.